Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic factors influencing cytarabine therapy.

Pharmacogenomics - 1 Oct 2009

Lamba Jatinder K

Abstract excerpt

The mainstay of acute myeloid leukemia chemotherapy is the nucleoside analog cytarabine (ara-C). Numerous studies suggest that the intracellular concentrations of the ara-C active metabolite, ara-CTP, vary widely among patients and, in turn, are associated with variability in clinical response to acute myeloid leukemia treatment. Thus, genetic variation in key genes in the ara-C metabolic pathway--specifically,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 5'-Nucleotidase
Share to Antimetabolites, Antineoplastic
Share to Cytarabine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytidine Deaminase

Share to Forecasting

Share to Leukemia, Myeloid, Acute

Share to Pharmacogenetics

Share to Ribonucleotide Reductases

Source

Open in PubMed Open full text

Identifiers

PMID: 19842938
DOI: 10.2217/pgs.09.118
PMCID: PMC2828057

Genes

RRM1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic factors influencing cytarabine therapy.PMID 19842938Read ↗

Variability in transport and biotransformation of cytarabine is associated with its toxicity in peripheral blood mononuclear cells.Semantic proximity Read ↗

Single nucleotide polymorphisms of cytarabine metabolic genes influence clinical outcome in acute myeloid leukemia patients receiving high-dose cytarabine therapy.Semantic proximity Read ↗

Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity.Semantic proximity Read ↗

Cytidine deaminase genetic variants influence RNA expression and cytarabine cytotoxicity in acute myeloid leukemia.Semantic proximity Read ↗

Impact of single nucleotide polymorphisms of cytarabine metabolic genes on drug toxicity in childhood acute lymphoblastic leukemia.Semantic proximity Read ↗

Comprehensive Ara-C SNP score predicts leukemic cell intracellular ara-CTP levels in pediatric acute myeloid leukemia patients.Semantic proximity Read ↗

Pharmacogenomics and the Treatment of Acute Myeloid LeukemiaSemantic proximity Read ↗

Combined interaction of multi-locus genetic polymorphisms in cytarabine arabinoside metabolic pathway on clinical outcomes in adult acute myeloid leukaemia (AML) patients.Semantic proximity Read ↗

Influence of UGT1A1 polymorphisms on the outcome of acute myeloid leukemia patients treated with cytarabine-base regimens.Semantic proximity Read ↗

UGT1A1 genotype influences clinical outcome in patients with intermediate-risk acute myeloid leukemia treated with cytarabine-based chemotherapy.Semantic proximity Read ↗

Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment.Semantic proximity Read ↗

RNA Expression of Genes Involved in Cytarabine Metabolism and Transport Predicts Cytarabine Response in Acute Myeloid LeukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.